Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Симптоматическое улучшение у больных раком легкого при лечении эрлотинибом (Тарцевой): анализ качества жизни в исследовании BR.21, проведенном Группой клинических исследований Национального института рака Канады
Симптоматическое улучшение у больных раком легкого при лечении эрлотинибом (Тарцевой): анализ качества жизни в исследовании BR.21, проведенном Группой клинических исследований Национального института рака Канады
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8–29.
2. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589–97.
3. Gandara D, Chansky K, Albain K et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group study S9504. J Clin Oncol 2003; 21: 2004–10.
4. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials–Nonsmall Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899–909.
5. Shepherd FA, Dancey J, Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–103.
6. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-smallcell lung cancer previously treated with platinumcontaining chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354–62.
7. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol: Classic Papers and Current Comments 2001; 6: 87–96.
8. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–46.
9. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149–58.
10. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 2004; 22: 3238–47.
11. Shepherd F, Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.
12. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
13. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635–42.
14. Cull A, Sprangers M, Bjordal K et al. EORTC Quality of Life Group Translation Procedure. EORTC Quality of Life Group Publication, 2002.
15. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment – The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995; 71: 633–6.
16. Osoba D, Rodrigues G, Myles J et al. Interpreting the significant changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–44.
17. Cella D, Eton D, Fairclough D et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol 2002; 55: 285–95.
18. Hochberg Y. A sharp Bonferroni procedure for multiple tests of significance. Biometrics 1988; 75: 800–2.
19. Osoba D, Bezjak A, Brundage M. et al. Analysis and interpretation of health-related quality-oflife data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 280–7.
20. Jansen SJ, Otten W, Stiggelbout AM. Review of determinants of patients’ preferences for adjuvant therapy in cancer. J Clin Oncol 2004; 22: 3181–90.
21. Koedoot CG, de Haan RJ, Stiggelbout AM et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice. Br J Cancer 2003; 89: 2219–26.
22. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 330–40.
23. Brundage M, Leis A, Bezjak A et al. Cancer patients’ preferences for communicating clinical trial quality of life information: A qualitative study. Qual Life Res 2003; 12: 395–404.
24. Bezjak A, Ng P, Skeel R et al. Predicting oncologists’ use of quality-of-life (QOL) data: Results of a survey of Eastern Co-operative Group (ECOG) physicians. Qual Life Res 2001; 10: 1–13.
25. Detmar SB, Muller MJ, Schornagel JH et al. Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol 2002; 20: 1056–62.
26. Brundage M, Pater J, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85: 1138–48.
27. Butler L, Bacon M, Carey M et al. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 2004; 22: 2461–8.
28. Gridelli C, Gallo C, Shepherd F et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025–34.
29. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome – UK NSCLC Gemcitabine Group: Non-Small Cell Lung Cancer. Br J Cancer 2000; 83: 447–53.
30. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
31. Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183–94.
2. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin vs observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589–97.
3. Gandara D, Chansky K, Albain K et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: Phase II Southwest Oncology Group study S9504. J Clin Oncol 2003; 21: 2004–10.
4. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials–Nonsmall Cell Lung Cancer Collaborative Group. BMJ 1995; 311: 899–909.
5. Shepherd FA, Dancey J, Ramlau R. et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–103.
6. Fossella FV, DeVore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-smallcell lung cancer previously treated with platinumcontaining chemotherapy regimens: The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354–62.
7. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol: Classic Papers and Current Comments 2001; 6: 87–96.
8. Fukuoka M, Yano S, Giaccone G et al. Multiinstitutional randomized phase II trial of gefitinib for previously treated patients with advanced nonsmall-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol 2003; 21: 2237–46.
9. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003; 290: 2149–58.
10. Perez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non–small-cell lung cancer. J Clin Oncol 2004; 22: 3238–47.
11. Shepherd F, Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–32.
12. Aaronson NK, Ahmedzai S, Bergman B et al. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international trials in oncology. J Natl Cancer Inst 1993; 85: 365–76.
13. Bergman B, Aaronson NK, Ahmedzai S et al. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQC30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30A: 635–42.
14. Cull A, Sprangers M, Bjordal K et al. EORTC Quality of Life Group Translation Procedure. EORTC Quality of Life Group Publication, 2002.
15. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: Implications for the evaluation of palliative treatment – The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer 1995; 71: 633–6.
16. Osoba D, Rodrigues G, Myles J et al. Interpreting the significant changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139–44.
17. Cella D, Eton D, Fairclough D et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592. J Clin Epidemiol 2002; 55: 285–95.
18. Hochberg Y. A sharp Bonferroni procedure for multiple tests of significance. Biometrics 1988; 75: 800–2.
19. Osoba D, Bezjak A, Brundage M. et al. Analysis and interpretation of health-related quality-oflife data from clinical trials: Basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2005; 41: 280–7.
20. Jansen SJ, Otten W, Stiggelbout AM. Review of determinants of patients’ preferences for adjuvant therapy in cancer. J Clin Oncol 2004; 22: 3181–90.
21. Koedoot CG, de Haan RJ, Stiggelbout AM et al. Palliative chemotherapy or best supportive care? A prospective study explaining patients’ treatment preference and choice. Br J Cancer 2003; 89: 2219–26.
22. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 330–40.
23. Brundage M, Leis A, Bezjak A et al. Cancer patients’ preferences for communicating clinical trial quality of life information: A qualitative study. Qual Life Res 2003; 12: 395–404.
24. Bezjak A, Ng P, Skeel R et al. Predicting oncologists’ use of quality-of-life (QOL) data: Results of a survey of Eastern Co-operative Group (ECOG) physicians. Qual Life Res 2001; 10: 1–13.
25. Detmar SB, Muller MJ, Schornagel JH et al. Role of health-related quality of life in palliative chemotherapy treatment decisions. J Clin Oncol 2002; 20: 1056–62.
26. Brundage M, Pater J, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Natl Cancer Inst 1993; 85: 1138–48.
27. Butler L, Bacon M, Carey M et al. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 2004; 22: 2461–8.
28. Gridelli C, Gallo C, Shepherd F et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025–34.
29. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome – UK NSCLC Gemcitabine Group: Non-Small Cell Lung Cancer. Br J Cancer 2000; 83: 447–53.
30. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
31. Dancey J, Shepherd FA, Gralla RJ et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with nonsmall-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183–94.
Авторы
________________________________________________
Источник: The New England Journal of Medicine.
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.